Alexandre Ciuffi Faustino
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Alexandre Ciuffi Faustino has a total of 7 co-authors. Here are the top co-authors by number of shared publications:
Ana Carolina Hamamura
Faculdade de Medicina de Ribeirao Preto (FMRP), Universidade de Sao Paulo, Ribeirao Preto, SP, BR
2 shared publicationsAnielle Freitas Bendo Danelichen
Faculdade de Medicina de Ribeirao Preto (FMRP), Universidade de Sao Paulo, Ribeirao Preto, SP, BR
1 shared publicationCaio Viani Arruda
Instituto de Biociencias, Universidade Estadual Paulista (UNESP), Botucatu, SP, BR
1 shared publication- Fernando Konjo Matsuura
Univ Sao Paulo, Fac Med Ribeirao Preto, Dept Imagens Med Oncol & Hematol, Ribeirao Preto, SP, Brazil
1 shared publication Gustavo Arruda Viani
Faculdade de Medicina de Ribeirao Preto (FMRP), Universidade de Sao Paulo, Ribeirao Preto, SP, BR
1 shared publication- Gustavo Arruda Viani
Ribeirão Preto Medical School, Department of Medical Imagings, Hematology and Oncology of University of São Paulo (FMRP-USP), Ribeirão Preto, Brazil; Latin America Cooperative Oncology Group (LACOG), Porto Alegre, Brazil
1 shared publication
Latest Publications
- Open Access
- 6 October 2022
- Published by Universidade de São Paulo. Agência de Bibliotecas e Coleções Digitais
Padrões de recorrência e desfecho de glioblastoma multiforme tratados com quimiorradioterapia e tremozolomida adjuvante
Introdução: Gliomas de alto grau são relativamente raros em adultos, porém são os tumores primários mais comuns do cérebro, sendo responsáveis por 2% de todas as neoplasias em adultos. Glioblastoma multiforme...
- 6 October 2022
- Published by Universidade de São Paulo. Agência de Bibliotecas e Coleções Digitais
Open AccessPadrões de recorrência e desfecho de glioblastoma multiforme tratados com quimiorradioterapia e tremozolomida adjuvante
Introdução: Gliomas de alto grau são relativamente raros em adultos, porém são os tumores primários mais comuns do cérebro, sendo responsáveis por 2% de todas as neoplasias em adultos. Glioblastoma multiforme...
- Open Access
Patterns of recurrence and outcomes of glioblastoma multiforme treated with chemoradiation and adjuvant temozolomide
To assess the patterns of failure and prognostic factors in Brazilian patients with glioblastoma multiforme (GBM) treated with radiotherapy (RT) and concurrent and adjuvant temozolomide (TMZ). Patients with diagnosed GBM post-resection received postoperative RT. TMZ was administered concurrently at 75 mg/m2/day for 28 consecutive days and adjuvant therapy at 150-200 mg/m2/day for 5 days every 28 days. Radiographic failure was defined as any new T1-enhancing lesion or biopsy-confirmed progressive enhancement inside of the radiation field. When possible, patients with recurrence were salvaged with metronomic TMZ, either in combination with a local treatment or alone (surgery or re-irradiation). Several prognostic factors were evaluated for overall survival (OS). Univariate and multivariate analyses were performed to identify significant factors. A p-value 70 at diagnosis (p=0.01), metronomic TMZ treatment (p=0.038), recursive partitioning analysis class III (p=0.03), and time to failure >9 months (p=0.0001). In multivariate analysis, the following factors remained significant for better OS: metronomic TMZ (p=0.01) and time to failure >9 months (p=0.0001). The median OS of Brazilian patients with GBM treated with RT and TMZ was satisfactory. Although TMZ therapy has become the standard of care for patients with newly diagnosed GBM, the recurrence rate is extremely high. Metronomic TMZ as salvage treatment improved survival in these patients.
Open AccessPatterns of recurrence and outcomes of glioblastoma multiforme treated with chemoradiation and adjuvant temozolomide
To assess the patterns of failure and prognostic factors in Brazilian patients with glioblastoma multiforme (GBM) treated with radiotherapy (RT) and concurrent and adjuvant temozolomide (TMZ). Patients with diagnosed GBM post-resection received postoperative RT. TMZ was administered concurrently at 75 mg/m2/day for 28 consecutive days and adjuvant therapy at 150-200 mg/m2/day for 5 days every 28 days. Radiographic failure was defined as any new T1-enhancing lesion or biopsy-confirmed progressive enhancement inside of the radiation field. When possible, patients with recurrence were salvaged with metronomic TMZ, either in combination with a local treatment or alone (surgery or re-irradiation). Several prognostic factors were evaluated for overall survival (OS). Univariate and multivariate analyses were performed to identify significant factors. A p-value 70 at diagnosis (p=0.01), metronomic TMZ treatment (p=0.038), recursive partitioning analysis class III (p=0.03), and time to failure >9 months (p=0.0001). In multivariate analysis, the following factors remained significant for better OS: metronomic TMZ (p=0.01) and time to failure >9 months (p=0.0001). The median OS of Brazilian patients with GBM treated with RT and TMZ was satisfactory. Although TMZ therapy has become the standard of care for patients with newly diagnosed GBM, the recurrence rate is extremely high. Metronomic TMZ as salvage treatment improved survival in these patients.
- Open Access
Palliative radiotherapy for gastric cancer: Is there a dose relationship between bleeding response and radiotherapy?
The aim of this study was to evaluate whether there is a relationship between bleeding response and radiotherapy dose to palliate patients with local recurrence or progression of gastric cancer (GC). To this end, we conducted a systematic review and meta-analysis ...
Open AccessPalliative radiotherapy for gastric cancer: Is there a dose relationship between bleeding response and radiotherapy?
The aim of this study was to evaluate whether there is a relationship between bleeding response and radiotherapy dose to palliate patients with local recurrence or progression of gastric cancer (GC). To this end, we conducted a systematic review and meta-analysis ...